default author photo

Yukari Nagasaka

National Cancer Center Hospital

Research Center for Cancer Prevention and Screenin

Tokyo

Japan

SCHOLARLY PAPERS

1

DOWNLOADS

157

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Durable Anti-Tumour Activity of the Multi-Targeted Inhibitor Lenvatinib in Patients with Advanced or Metastatic Thymic Carcinoma: A Multicentre Phase II (REMORA) Trial

Number of pages: 52 Posted: 05 Feb 2020
Jun Sato, Miyako Satouchi, Shoichi Itoh, Yusuke Okuma, Seiji Niho, Hidenori Mizugaki, Haruyasu Murakami, Yasuhito Fujisaka, Toshiyuki Kozuki, Kenichi Nakamura, Yukari Nagasaka, Mamiko Kawasaki, Tomoaki Yamada, Ryunosuke Machida, Aya Kuchiba, Yuichiro Ohe and Noboru Yamamoto
National Cancer Center Hospital - Department of Experimental Therapeutics, Hyogo Cancer Center, Hyogo Cancer Center, Komagome Hospital - Tokyo Metropolitan Cancer and Infectious Diseases Center, National Cancer Center Hospital East, Hokkaido University, Shizuoka Cancer Center - Division of Thoracic Oncology, Osaka Medical College, National Hospital Organization Shikoku Cancer Center, National Cancer Center Hospital, National Cancer Center Hospital, National Cancer Center Hospital, National Cancer Center Hospital, National Cancer Center Hospital, National Cancer Center Hospital, National Cancer Center Hospital and National Cancer Center Hospital - Department of Experimental Therapeutics
Downloads 157 (474,889)

Abstract:

Loading...

Lenvatinib; thymic carcinoma; phase II; multi-targeted inhibitor